Novo Nordisk Projects Slower Growth for 2025 Despite Wegovy’s Strong Q4 Performance

Novo Nordisk reported a 30% increase in Q4 2024 sales, reaching approximately $12.25 billion (85.68 billion Danish kroner)2.

Wegovy sales more than doubled in Q4 2024, with a 107% increase at constant exchange rates to 19.87 billion Danish kroner7.

For 2025, Novo Nordisk forecasts sales growth between 16% and 24% at constant exchange rates, lower than the 26% growth achieved in 20244.

The company cites "intensifying competition and continued pricing pressure within Diabetes and Obesity care" as factors influencing the 2025 guidance7.

Novo Nordisk plans to file for the first regulatory approval of its new weight-loss drug CagriSema during the first quarter of 20267.

The company is focusing on commercial execution, R&D pipeline progression, and production capacity expansion in 20254.

Novo Nordisk's U.S.-listed shares rose 4% in premarket trading following the Q4 results announcement7.

The global market for obesity treatments is expanding, with the World Obesity Federation estimating that over 4 billion individuals will be overweight or obese by 20355.

Sources:

2. https://www.benzinga.com/25/02/43491991/novo-nordisk-records-more-than-double-wegovy-sales-in-q4-seeks-regulatory-approval-for-hybrid-weight-loss-drug-in-2026

4. https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=915255

5. https://www.statista.com/statistics/1416998/sales-wegovy-novo-nordisk-by-quarter/

7. https://www.investopedia.com/novo-nordisk-stock-rises-as-wegovy-sales-power-better-than-estimated-results-8786145